Top

International Journal of Colorectal Disease

Published in:

Open Access 01-04-2012 | Original Article

A double-blind placebo-controlled trial to study therapeutic effects of probiotic Escherichia coli Nissle 1917 in subgroups of patients with irritable bowel syndrome

Authors: Wolfgang Kruis, Sigrun Chrubasik, Stephan Boehm, Christiane Stange, Juergen Schulze

Published in: International Journal of Colorectal Disease | Issue 4/2012

Abstract

Purpose

To study the therapeutic effects of probiotic Escherichia coli Nissle 1917 (EcN) in irritable bowel syndrome (IBS) and identify subgroups benefiting most.

Background

Some trials investigating therapeutic effects in irritable bowel syndrome have shown benefits in IBS subgroups only. Probiotic treatment seems to be promising.

Methods

Patients with irritable bowel syndrome (120; Rome II) were recruited to a prospective double-blind study and randomized to either EcN (n = 60) or placebo (n = 60) given for 12 weeks. Objectives were to describe efficacy and safety of EcN in different groups of irritable bowel syndrome. Outcome was assessed by ‘Integrative Medicine Patient Satisfaction Scale’.

Results

Altogether, the responder rate was higher in the EcN than in the placebo group. However, only after 10 and 11 weeks, the differences were significant (Δ 20.0% points [95% CI 2.6; 37.4], p = 0.01 and Δ 18.3% points [95% CI 1.0; 35.7], p = 0.02, respectively). The best response was observed in the subgroup of patients with gastroenteritis or antibiotics prior to irritable bowel syndrome onset (Δ 45.7% points, p = 0.029). No significant differences were observed in any other subgroup. Both treatment groups showed similar adverse events and tolerance.

Conclusions

Probiotic EcN shows effects in irritable bowel syndrome, especially in patients with altered enteric microflora, e.g. after gastroenterocolitis or administration of antibiotics.

Camilleri M (2001) Management of the irritable bowel syndrome. Gastroenterology 120(3):652–668PubMedCrossRef

Quigley EMM, Flourie B (2007) Probiotics and irritable bowel syndrome: a rationale for their use and an assessment of the evidence to date. Neurogastroenterol Motil 19(3):166–172PubMedCrossRef

McFarland LV, Dublin S (2008) Meta-analysis of probiotics for the treatment of irritable bowel syndrome. World J Gastroenterol 14(17):2650–2661PubMedCrossRef

Fuller R (1989) Probiotics in man and animals. J Appl Bacteriol 66(5):365–378PubMedCrossRef

FAO, WHO. Health and nutritional properties of probiotics in food including powder milk with live lactic acid bacteria. Report of a joint FAO/WHO expert consultation on evaluation of health and nutritional properties of probiotics in food including powder milk with live lactic acid bacteria. Cordoba, Argentina, 1–4 October 2001. http://www.who.int/foodsafety/publications/fs_management/en/probiotics.pdf

Grozdanov L, Raasch C, Schulze J et al (2004) Analysis of the genome structure of the nonpathogenic probiotic Escherichia coli strain Nissle 1917. J Bacteriol 186(16):5432–5441PubMedCrossRef

Grozdanov L, Zähringer U, Blum-Oehler G et al (2002) A single nucleotide exchange in the wzy gene is responsible for the semirough O6 lipopolysaccharide phenotype and serum sensitivity of Escherichia coli strain Nissle 1917. J Bacteriol 184(21):5912–5925PubMedCrossRef

Sonnenborn U, Schulze J (2009) The non-pathogenic Escherichia coli strain Nissle 1917—features of a versatile probiotic. Microb Ecol Health Dis 21(3–4):122–58CrossRef

Möllenbrink M, Bruckschen E (1994) Behandlung der chronischen Obstipation mit physiologischen Escherichia-coli-Bakterien. Ergebnisse einer klinischen Studie zur Wirksamkeit und Verträglichkeit der mikrobiologischen Therapie mit dem E.-coli-Stamm Nissle 1917 (Mutaflor) [Treatment of chronic constipation with physiologic Escherichia coli bacteria. Results of a clinical study of the effectiveness and tolerance of microbiological therapy with the E. coli Nissle 1917 strain (Mutaflor)]. Med Klin 89(11):587–593

10.

Henker J, Laass M, Blokhin BM et al (2007) The probiotic Escherichia coli strain Nissle 1917 (EcN) stops acute diarrhoea in infants and toddlers. Eur J Pediatr 166(4):311–318PubMedCrossRef

11.

Henker J, Laass MW, Blokhin BM et al (2008) Probiotic Escherichia coli Nissle 1917 versus placebo for treating diarrhea of greater than 4 days duration in infants and toddlers. Pediatr Infect Dis J 27(6):494–499PubMedCrossRef

12.

Kruis W, Fric P, Pokrotnieks J et al (2004) Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine. Gut 53(11):1617–1623PubMedCrossRef

13.

Thompson WG, Longstreth GF, Drossman DA et al (1999) Functional bowel disorders and functional abdominal pain. Gut 45(suppl II):43–47

14.

Kruis W, Thieme C, Weinzierl M et al (1984) A diagnostic score for the irritable bowel syndrome. Its value in the exclusion of organic disease. Gastroenterology 87(1):1–7PubMed

15.

Steinsbekk A, Biolchini J, Heger M, Rezzani C, Tsamis N, van Haselen R et al (1999) Data collection in homeopathic practice: a proposal for an international standard. European Committee for Homeopathy. Data Collection Group (DCG), Trondheim, Norway

16.

Wong E, Guyatt GH, Cook DJ et al (1998) Development of a questionnaire to measure quality of life in patients with irritable bowel syndrome. Eur J Surg 164(suppl 583):50–56CrossRef

17.

Chang L (2008) The trials and tribulations of drug development for functional gastrointestinal disorders. Neurogastroenterol Motil 20(Suppl 1):130–138PubMedCrossRef

18.

Brenner DM, Moeller MJ, Chey WD et al (2009) The utility of probiotics in the treatment of irritable bowel syndrome: a systematic review. Am J Gastroenterol 104(4):1033–1049PubMedCrossRef

19.

Talley NJ (2006) A unifying hypothesis for the functional gastrointestinal disorders: really multiple diseases or one irritable gut? Rev Gastroenterol Disord 6(2):72–78PubMed

20.

Mertz HR (2003) Irritable bowel syndrome. N Engl J Med 349(22):2136–2146PubMedCrossRef

21.

Whorwell PJ, Altringer L, Morel J et al (2006) Efficacy of an encapsulated probiotic Bifidobacterium infantis 35624 in women with irritable bowel syndrome. Am J Gastroenterol 101(7):1581–1590PubMedCrossRef

22.

Spiller RC (2003) Postinfectious irritable bowel syndrome. Gastroenterology 124(6):1662–1671PubMedCrossRef

23.

Halvorson HA, Schlett CD, Riddle MS (2006) Postinfectious irritable bowel syndrome—a meta-analysis. Am J Gastroenterol 101(8):1894–1899PubMedCrossRef

24.

Collins SM (1996) The immunomodulation of enteric neuromuscular function: implications for motility and inflammatory disorders. Gastroenterology 111(6):1683–1699PubMedCrossRef

25.

Spiller RC (2004) Infection, immune function, and functional gut disorders. Clin Gastroenterol Hepatol 2(6):445–455PubMedCrossRef

26.

Hawrelak JA, Myers SP (2004) The causes of intestinal dysbiosis: a review. Altern Med Rev 9(2):180–197PubMed

27.

Maxwell PR, Rink E, Kumar D et al (2002) Antibiotics increase functional abdominal symptoms. Am J Gastroenterol 97(1):104–108PubMedCrossRef

28.

O'Mahony L, McCarthy J, Kelly P et al (2005) Lactobacillus and Bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles. Gastroenterology 128(3):541–551PubMedCrossRef

29.

Helwig U, Lammers KM, Rizzello F et al (2006) Lactobacilli, bifidobacteria and E. coli Nissle induce pro- and anti-inflammatory cytokines in peripheral blood mononuclear cells. World J Gastroenterol 12(37):5978–5986PubMed

30.

Bär F, von Koschitzky H, Roblick U et al (2009) Cell-free supernatants of Escherichia coli Nissle 1917 modulate human colonic motility: evidence from an in vitro organ bath study. Neurogastroenterol Motil 21:559–566PubMedCrossRef

31.

Altenhoefer A, Oswald S, Sonnenborn U et al (2004) The probiotic Escherichia coli strain Nissle 1917 interferes with invasion of human intestinal epithelial cells by different enteroinvasive bacterial pathogens. FEMS Immunol Med Microbiol 40(3):223–229PubMedCrossRef

32.

Wehkamp J, Harder J, Wehkamp K et al (2004) NF-k-B- and AP-1-mediated induction of human beta defensin-2 in intestinal epithelial cells by Escherichia coli Nissle 1917: a novel effect of a probiotic bacterium. Infect Immun 72(10):5750–5758PubMedCrossRef

33.

Cichon C, Enders C, Sonnenborn U et al (2004) DNA-microarray-based comparison of cellular responses in polarized T84 epithelial cells triggered by probiotics: E. coli Nissle 1917 (EcN) and Lactobacillus acidophilus PZ1041. Gastroenterology 126(4):A-578–A-579

Title: A double-blind placebo-controlled trial to study therapeutic effects of probiotic Escherichia coli Nissle 1917 in subgroups of patients with irritable bowel syndrome
Authors: Wolfgang Kruis
Sigrun Chrubasik
Stephan Boehm
Christiane Stange
Juergen Schulze
Publication date: 01-04-2012
Publisher: Springer-Verlag
Published in: International Journal of Colorectal Disease / Issue 4/2012
Print ISSN: 0179-1958
Electronic ISSN: 1432-1262
DOI: https://doi.org/10.1007/s00384-011-1363-9

Keynote webinar | Spotlight on medication adherence

Springer Medicine

A double-blind placebo-controlled trial to study therapeutic effects of probiotic Escherichia coli Nissle 1917 in subgroups of patients with irritable bowel syndrome

Abstract

Purpose

Background

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 4/2012

NF-κB p65 phosphorylated at serine-536 is an independent prognostic factor in Swedish colorectal cancer patients

Biological mesh reconstruction of perineal wounds following enhanced abdominoperineal excision of rectum (APER)

Institution learning curve of laparoscopic colectomy—a multi-dimensional analysis

A randomized controlled trial of anorectal biofeedback for constipation

Stapled and conventional Milligan–Morgan haemorrhoidectomy: different solutions for different targets

Local hemostatic effect of cellulose tampons (Tampax) after stapled hemorrhoidopexy